merck and squibb corp will benefit from study shows lower levels blood cholesterol slows build fat heart arteries lowering risk heart attacks industry analysts said both companies have developed drugs slow body production cholesterol although merck about months ahead squibb with drug expected approved this year certainly this study will create greater acceptance anti cholesterol drugs said robert uhl drug analyst eberstadt fleming although neither company drug was used study which was conducted team scientists university southern california school medicine both leaders new class drugs fight cholesterol study reported journal american medical association showed lower levels cholesterol achieved through combination drugs and special diet slowed and some cases reversed build fatty deposits heart arteries such build leads heart attacks leading death health officials have said lower levels cholesterol could immediately benefit six mln americans suffer symptoms coronary artery disease study advocated reduction cholesterol some mln americans anti cholesterol crusade gains momentum industry analysts and executives believe healthier diet and drug therapy will gain wider acceptance this context pharmaceutical analyst david crossen sanford bernstein said culture can shift terms drug treatment because some people arn going fundamentally alter diets worldwide anti cholesterol drug market valued 600 mln dlrs year but new drugs reach market analysts estimate revenues will swell billion dlrs annually about next five years drugs used study combination with low cholesterol diet were niacin common compound and colestipol drug upjohn has sold since 1977 but these two drugs have some drawbacks analysts new drugs from merck and squibb avoid niacin leads tremendous amounts flushing constipation stomach upset crossen said colestipol sand powder comes dosage grams and must mixed with glass water isn fun crossen said drug analyst uhl said drawbacks restricted upjohn sales for drug which said under mln dlrs year contrast new drugs from merck and squibb have little side effects because target factor body production cholesterol enzyme found liver past methods getting down cholesterol have been rather variable said charles sanders executive vice president squibb new drugs contrast interupt clear step cholesterol production sanders said also new drugs easier since tablet form swallowed once twice day merck drug mevacor received recommendation from advisory panel food and drug administration earlier this year and expected receive full approval for sale summer fall squibb drug eptastatin expected submitted for regulatory approval first second quarter 1988 sanders said warner lambert and bristol meyers also have cholesterol fighting compounds similar upjohn drug but only merck and upjohn ahead new class cholesterol inhibitors reuter 